Welcome to our dedicated page for Evaxion Biotech A/S American Depositary Share news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S American Depositary Share stock.
Evaxion Biotech A/S (symbol: EVAX) is a clinical-stage biotechnology company founded in 2008 with the mission to address some of the most significant global health challenges using artificial intelligence (AI). The company has developed robust platforms for creating novel vaccines and therapies. Evaxion's primary AI platforms, PIONEER and EDEN, utilize advanced in silico tools including big data, AI, and supercomputing to predict, rank, and optimize epitopes and antigens that stimulate highly protective immune responses against cancers and infectious diseases.
Evaxion's EDEN platform focuses on the rapid discovery of new antigens eliciting cross-protective immune responses against bacterial pathogens. On the other hand, the PIONEER platform identifies epitopes of mutated proteins to activate the body's natural immune responses. Additionally, the company has developed two more AI platforms, RAVEN and ObsERV, to further enhance its drug development pipeline.
The company's leading product candidates include EVX-01 and EVX-02, which are under development for cancer treatment, as well as EVX-03, a pre-clinical candidate for non-small-cell lung cancer (NSCLC). With a strong focus on AI-driven drug discovery and development, Evaxion aims to create innovative immunotherapies with improved efficacy for patients with unmet medical needs.
Recent news highlights key company activities, such as:
- A replay of the R&D Day presentations is available on the company's website.
- Information about the EVX-01 Phase 2 clinical trial.
- The company resolved a Nasdaq equity deficiency issue stemming from the IFRS accounting treatment of investor warrants.
To learn more about Evaxion Biotech A/S and its innovative AI-driven approaches, please visit Evaxion Biotech.
Evaxion Biotech (NASDAQ: EVAX) reported promising results from its Phase 1/2a trial of EVX-01 in metastatic melanoma. The therapy, combined with anti-PD1 treatment, resulted in a 67% Objective Response Rate (ORR), with 22% achieving complete responses and 44% partial responses. The study demonstrated a favorable safety profile, noting only Grade 1 and 2 adverse events. The company plans to advance EVX-01 into a Phase 2 trial by December 2021 and has generated data from the EVX-02 trial, showing T-cell activation. Overall, these findings support the innovative AI-Immunology platform, PIONEER.
Evaxion Biotech (NASDAQ: EVAX) announced a conference call on July 8, 2021, to discuss the Phase 1/2a data for its products EVX-01 and EVX-02. The call will feature CEO Lars Wegner, CFO Glenn Vraniak, and co-founder CBO Niels Iversen Moller, starting at 8:00 a.m. EDT. This event will provide insights on Evaxion's AI-driven immunotherapy development efforts for cancer and other diseases. The results are crucial for evaluating the company's growth potential and product pipeline. A live webcast will be available on Evaxion's Investor Relations page.
Evaxion Biotech (Nasdaq: EVAX) announced the acceptance of a scientific paper at ICML 2021. The paper, titled “Efficient Generative Modelling of Protein Structure Fragments using a Deep Markov Model,” presents BIFROST, a predictive system that converts sequence data into protein structure information, aiding drug and vaccine design. BIFROST's Bayesian approach improves the reliability of predictions, making it suitable for drug development with incomplete datasets. The company aims to integrate these advancements into its AI platforms for enhanced vaccine development.
Evaxion Biotech A/S (NASDAQ: EVAX) announced new preclinical data from its AICoV program, aimed at developing next-generation vaccines against coronaviruses. Utilizing the RAVEN AI platform, the program identifies novel immunogenic T cell epitopes beyond the spike protein, enhancing vaccine design against variants. Key advantages include overcoming variant effectiveness issues and eliminating cold storage needs. Initial animal studies showed promising immune responses comparable to human sera. The AICoV initiative receives support from international investors and Innovation Fund Denmark.
Evaxion Biotech (NASDAQ: EVAX) announced the election of Lars Holtug to its Board of Directors during the Annual General Meeting on May 25, 2021. Holtug, a seasoned financial professional with extensive experience in the healthcare sector, will chair the Audit Committee, succeeding Helen M. Boudreau. Chairwoman Marianne Søgaard expressed confidence that Holtug's background in the biotech industry and his past roles, including at PwC, will be beneficial as Evaxion progresses its clinical programs targeting cancer and infectious diseases.
Evaxion Biotech A/S (NASDAQ: EVAX) announced its Q1 2021 financial results, reporting cash reserves of $27 million as of March 31, 2021. Following a successful IPO raising $30 million, Evaxion is advancing its lead product candidates, EVX-01 and EVX-02, with Phase 1/2a data expected late Q2 2021. R&D expenses increased to $3.9 million, reflecting growth in clinical trials and staffing. The company reported a net loss of $4.1 million for the quarter. Overall, the financial position supports continued development of key programs and a cash runway extending into 2022.
Evaxion Biotech (NASDAQ: EVAX) will present its Q1 2021 financial results on May 13, 2021. CEO Lars Wegner and CFO Glenn Vraniak will lead an earnings call at 8:30 a.m. EDT. Dial-in numbers: US: 877-407-0792, International: +1-201-689-8263, Conference ID: 13718732. An audio webcast will be available on Evaxion's website. The company develops AI-driven immunotherapies targeting cancer and infectious diseases, with a pipeline including three patient-specific cancer treatments currently in Phase 1/2a trials.
Evaxion Biotech (Nasdaq: EVAX) announced a significant presentation by Dr. Jens Kringelum at the 4th Neoantigen Summit Europe, focusing on AI's role in personalized cancer medicine. The discussion highlighted advancements in predicting cancer neoepitopes using peptide-MHC complex stability. Evaxion's AI platform, PIONEER, is continuously evolving, leveraging new methods for enhanced immunotherapy design. CEO Lars Wegner emphasized the efficiency gains in drug development from these improvements. The company is developing a range of patient-specific immunotherapies and vaccines to address bacterial and viral infections.
Evaxion Biotech A/S (Nasdaq: EVAX) reported strong progress in its Q4 and full year 2020 results, highlighted by a successful IPO in February 2021 that raised $30 million. The company has cash reserves of $5.8 million as of Dec 31, 2020, which have been bolstered by IPO proceeds, ensuring funding into 2022. Clinical trials for their cancer vaccine EVX-02 are on track, with anticipated data releases in Q2 2021. However, the company reported a net loss of $15 million for 2020 with increased R&D and administrative expenses compared to the previous year.
Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology firm, will announce its 2020 financial results on April 6, 2021. CEO Lars Wegner and CFO Glenn Vraniak will lead an earnings call at 8:30 a.m. EDT. Evaxion specializes in AI-driven immunotherapies targeting cancer and infectious diseases, with a pipeline that includes three patient-specific cancer immunotherapies in development and a preclinical vaccine program against S. aureus, including MRSA. Interested parties can access dial-in and webcast details through provided links.
FAQ
What is the current stock price of Evaxion Biotech A/S American Depositary Share (EVAX)?
What is the market cap of Evaxion Biotech A/S American Depositary Share (EVAX)?
What does Evaxion Biotech A/S specialize in?
What are the main AI platforms used by Evaxion Biotech?
What are Evaxion's leading product candidates?
What recent developments have taken place at Evaxion Biotech?
When was Evaxion Biotech A/S founded?
How does the EDEN platform contribute to Evaxion's research?
What is PIONEER platform's role in Evaxion's operations?
What kind of financial challenges has Evaxion recently addressed?
Where can I find more information about Evaxion's recent activities?
What is the mission of Evaxion Biotech A/S?
